OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ovid Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.17+0.02 (+0.93%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ovid Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| Market Cap | $423.80M | $197.05M |
| Enterprise Value | $254.03M | $106.56M |
| PS Ratio | 267.72 | 3.93 |
| PB Ratio | 2.02 | 2.14 |
| P/TBV Ratio | 2.02 | 2.46 |
Enterprise value
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 160.47 | 2.69 |
Income (trailing twelve months)
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| Revenue | $1.58M | $57.94M |
| Operating Income | -$58.36M | -$21.44M |
| Pretax Income | -$34.49M | -$14.45M |
| Net Income | -$34.49M | -$22.46M |
| EBITDA | -$58.28M | -$16.91M |
Margins
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -3686.7% | -44.5% |
| Pretax Margin | -2178.9% | -13.0% |
| Profit Margin | -2178.9% | -39.2% |
| EBITDA Margin | -3681.4% | -31.3% |
Returns
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -26.0% | -53.1% |
| Return on Assets (ROA) | -22.3% | -41.0% |
| Return on Invested Capital (ROIC) | -160.2% | -32.0% |
| Return on Capital Employed (ROCE) | -26.3% | -37.8% |
Growth
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -76.2% | 6.01% |
| Revenue Growth (3Y CAGR) | 69.0% | 2.25% |
| Revenue Growth (5Y CAGR) | -10.5% | 6.42% |
Balance sheet
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $169.77M | $62.42M |
| Net Cash (Debt) | $169.77M | $15.68M |
| Net Cash Per Share | $0.87 | $0.65 |
| Equity (Book Value) | $209.89M | $48.79M |
| Book Value Per Share | $1.07 | $1.36 |
| Tangible Book Value | $209.89M | $23.06M |
| Working Capital | $113.64M | $75.77M |
Financial position
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 12.39 | 3.30 |
| Quick Ratio | 17.01 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$54.77M | -$12.35M |
Efficiency
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.38 |
| Revenue Per Employee | $68.83K | $398.96K |
| Profits Per Employee | -$1.50M | -$732.08K |
| Employee Count | 23 | 73 |
Dividends and yields
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -8.14% | -21.2% |
Shares
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 195,298,000 | 59,128,900 |
| Shares Change (QoQ) | 10.5% | 0.54% |
| Float | 168,656,000 | 48,744,500 |
| Shares Held by Insiders | 13.6% | 11.8% |
| Shares Held by Institutions | 75.3% | 59.4% |
Taxes
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Ovid Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 9.14 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Ovid Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.